An open-label, dose escalation and expansion clinical trial to evaluate the safety,
tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic
colorectal cancer and metastatic breast cancer.
The study is an open-label, dose escalation and expansion clinical trial to evaluate the
safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. The
study will consist of two phases:
A dose escalation phase - A 3+3 design will be used for this portion of the study.
A dose expansion phase - Five cohorts will be evaluated in Dose Expansion. Cohort A will
evaluate the MTD/RP2D in patients with advanced solid tumors. Cohort B and Cohort C will
evaluate the MTD/RP2D in metastatic colorectal cancer patients. Cohort D and Cohort E
will evaluate the MTD/RP2D in metastatic breast cancer patients.
Study will be conducted in up to 9 sites in the US.
Diet and Nutrition,
Chronic Shoulder Pain,
Adverse Effects, Drugs,
Breast Cancer - HER2 Positive,
Near-Sighted Corrective Surgery,
Colon Cancer Screening,
Colon cancer; rectal cancer,
Advanced Solid Tumors,
Metastatic Breast Cancer,
Peripheral Arterial Occlusive Disease,
Triple Negative Breast Cancer,
HER2 Negative Breast Cancer,
Stage IV Breast Cancer,
Metastatic Colon Cancer,
Recurrent Respiratory Papillomatosis,
Razor Bumps (Pseudofolliculitis Barbae),
Metastatic Triple-Negative Breast Cancer,
Hormone Receptor Positive Breast Carcinoma,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.